Sentences with phrase «ibrutinib for»
The US Food and Drug Administration (FDA) recently approved the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.
http://www.cancernetwork.com/
The team will present on the first 10 patients in the trial, each of whom had been taking ibrutinib for at least six months but had not achieved a complete remission.
Patients in the trial had been on ibrutinib for a minimum of six months and had not achieved a complete response when they received an infusion of engineered cells split over three consecutive days.
Not exact matches
«This single - institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation.
«Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»
Longer follow - up will reveal the durability of these results, the authors said, and may support the evaluation of a first - line approach with ibrutinib and CAR therapy in an effort to remove the need for chronic therapy.
The target for ibrutinib, an enzyme called Bruton's tyrosine kinase (BTK), is a key component of B - cell receptor signaling.
For example, a drug called ibrutinib has been tested in clinical trials to treat an aggressive form of non-Hodgkin lymphoma, diffuse large B - cell lymphoma (DLBCL).
FDA Approved Ibrutinib for Relapsed, Refractory Marginal Zone Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 therapy.